Skip to content
10-Q

Quarterly Report

Acurx Pharmaceuticals, Inc. ACXP

0001104659-26-058631

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 4.3M sh
Shares Diluted Q1 2026 · Mar 31, 2026 2.72M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 1M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.41M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.05M
Stockholders Equity Q1 2026 · Mar 31, 2026 $7.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.27M
Stockholders Equity Q1 2026 · Mar 31, 2025 $2.31M
Stockholders Equity Q1 2026 · Dec 31, 2024 $615.12K
Current Liabilities Q1 2026 · Mar 31, 2026 $2.53M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.42M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.53M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.42M
Total Assets Q1 2026 · Mar 31, 2026 $9.54M
Total Assets Q1 2026 · Dec 31, 2025 $7.69M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.62
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$2.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.62
Eps Basic restated Q1 2026 · Mar 31, 2025 −$2.15
Rd Expense Q1 2026 · Mar 31, 2026 $341.47K
Rd Expense Q1 2026 · Mar 31, 2025 $598.8K
Net Income Q1 2026 · Mar 31, 2026 −$1.68M
Net Income Q1 2026 · Mar 31, 2025 −$2.15M
Operating Income Q1 2026 · Mar 31, 2026 −$1.72M
Operating Income Q1 2026 · Mar 31, 2025 −$2.18M